Enliven Therapeutics, Inc. (ELVN) stock
ELVNNasdaqPharmaceutical PreparationsFiscal year ends December 31
$46.85−0.77 (-1.62%)
Close on Nov 17, 2026Market cap $3.43BP/E –Yield –
Enliven Therapeutics cash
Cash and short-term investments held at the end of each period.
Enliven Therapeutics's cash was $895.20M at Jun 30, 2026. For fiscal 2025 it was $462.60M, up 47.6% from the year before. The highest annual figure on record is $462.60M in fiscal 2025.
Annual cash
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $462.60M | +47.6% |
| FY2024 | Dec 31, 2024 | $313.40M | +23.8% |
| FY2023 | Dec 31, 2023 | $253.10M | +234.8% |
| FY2022 | Dec 31, 2022 | $75.59M | -16.3% |
| FY2021 | Dec 31, 2021 | $90.30M | +2.4% |
| FY2020 | Dec 31, 2020 | $88.20M | +204.2% |
| FY2019 | Dec 31, 2019 | $29.00M | +292.8% |
| FY2018 | Dec 31, 2018 | $7.38M | – |
Quarterly cash
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $895.20M | +82.5% |
| Q1 FY2026 | Mar 31, 2026 | $452.40M | +56.2% |
| Q4 FY2025 | Dec 31, 2025 | $462.60M | +47.6% |
| Q3 FY2025 | Sep 30, 2025 | $477.60M | +63.7% |
| Q2 FY2025 | Jun 30, 2025 | $490.50M | +57.0% |
| Q1 FY2025 | Mar 31, 2025 | $289.60M | -9.6% |
| Q4 FY2024 | Dec 31, 2024 | $313.40M | +23.8% |
| Q3 FY2024 | Sep 30, 2024 | $291.80M | +10.7% |
| Q2 FY2024 | Jun 30, 2024 | $312.40M | +12.4% |
| Q1 FY2024 | Mar 31, 2024 | $320.50M | +9.7% |
| Q4 FY2023 | Dec 31, 2023 | $253.10M | +234.8% |
| Q3 FY2023 | Sep 30, 2023 | $263.50M | +368.0% |
| Q2 FY2023 | Jun 30, 2023 | $277.90M | +360.9% |
| Q1 FY2023 | Mar 31, 2023 | $292.10M | +300.7% |
| Q4 FY2022 | Dec 31, 2022 | $75.59M | -16.3% |
| Q3 FY2022 | Sep 30, 2022 | $56.30M | -45.2% |
| Q2 FY2022 | Jun 30, 2022 | $60.30M | -9.7% |
| Q1 FY2022 | Mar 31, 2022 | $72.90M | -3.6% |
| Q4 FY2021 | Dec 31, 2021 | $90.30M | +2.4% |
| Q3 FY2021 | Sep 30, 2021 | $102.80M | +7.0% |
| Q2 FY2021 | Jun 30, 2021 | $66.80M | -37.2% |
| Q1 FY2021 | Mar 31, 2021 | $75.60M | -28.6% |
| Q4 FY2020 | Dec 31, 2020 | $88.20M | +204.2% |
| Q3 FY2020 | Sep 30, 2020 | $96.10M | +462.4% |
| Q2 FY2020 | Jun 30, 2020 | $106.30M | +135.0% |
| Q1 FY2020 | Mar 31, 2020 | $105.90M | +116.6% |
| Q4 FY2019 | Dec 31, 2019 | $29.00M | +292.8% |
| Q3 FY2019 | Sep 30, 2019 | $17.09M | – |
| Q2 FY2019 | Jun 30, 2019 | $45.23M | – |
| Q1 FY2019 | Mar 31, 2019 | $48.90M | – |
| Q4 FY2018 | Dec 31, 2018 | $7.38M | – |
See a number that looks wrong?